Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-( 4-morpholin-4-ylmethyl-phenyl)-isoxazo le-3-carboxylic acid ethylamide and formulations comprising these forms

Details for Australian Patent Application No. 2008220800 (hide)

Owner Vernalis (R&D) Ltd. Novartis AG

Inventors Mutz, Michael; Dymock, Brian William; Petersen, Holger; Zheng, Weijia; Krell, Christoph; Drysdale, Martin James

Agent Davies Collison Cave

Pub. Number AU-B-2008220800

PCT Pub. Number WO2008/104595

Priority 07103346.8 01.03.07 EP

Filing date 28 February 2008

Wipo publication date 4 September 2008

Acceptance publication date 16 February 2012

International Classifications

C07D 295/00 (2006.01) Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

A61K 31/5377 (2006.01)

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

3 September 2009 PCT application entered the National Phase

  PCT publication WO2008/104595 Priority application(s): WO2008/104595

16 February 2012 Application Accepted

  Published as AU-B-2008220800

14 June 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008220821-A method of identification of cells that show sensitivity to modulation of signaling mediated by a Fibroblast Growth Factor Receptor or a variant thereof

2008220795-Novel dosage form